AI Article Synopsis
- A patient with pulmonary marginal zone B-cell lymphoma (MALT) was resistant to traditional chemotherapy treatments.
- After receiving one four-week treatment of rituximab, she experienced significant improvement in her pulmonary lesions.
- Nineteen months after completing her treatment, she remains free from disease progression, highlighting rituximab's potential effectiveness for this condition.
Article Abstract
We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 months after finishing her treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190500137890 | DOI Listing |
Publication Analysis
Top Keywords
regression pulmonary
8
pulmonary malt
8
malt lymphoma
8
lymphoma treatment
4
treatment rituximab
4
rituximab describe
4
describe patient
4
patient extranodal
4
extranodal pulmonary
4
pulmonary marginal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!